{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:00:07Z","timestamp":1762142407814,"version":"3.37.3"},"reference-count":10,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiatives 2 Joint Undertaking. This Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA.","award":["116106"],"award-info":[{"award-number":["116106"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Currently there are no general guidelines for diagnosis or management of suspected drug-induced (DI) interstitial lung disease (ILD). The objective was to survey a sample of current European practice in the diagnosis and management of DI-ILD, in the context of the prescribing information approved by regulatory authorities for 28 licenced drugs with a recognised risk of DI-ILD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consultant physicians working in specialist ILD centres across Europe were emailed two surveys<jats:italic>via<\/jats:italic>a website link. Initially, opinion was sought regarding various diagnostic and management options based on seven clinical ILD case vignettes and five general questions regarding DI-ILD. The second survey involved 29 statements regarding the diagnosis and management of DI-ILD, derived from the results of the first survey. Consensus agreement was defined as 75% or greater.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When making a diagnosis of DI-ILD, the favoured investigations used (other than computed tomography) included pulmonary function tests, bronchoscopy and blood tests. The preferred method used to decide when to stop treatment was a pulmonary function test. In the second survey, the majority of the statements were accepted by the 33 respondents, with only four of 29 statements not achieving consensus when the responses \u201cagree\u201d and \u201cstrongly agree\u201d were combined as one answer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The two surveys provide guidance for clinicians regarding an approach to the diagnosis and management of DI-ILD in which the current evidence base is severely lacking, as demonstrated by the limited information provided by the manufacturers of the drugs associated with a high risk of DI-ILD that we reviewed.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00286-2019","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T13:54:32Z","timestamp":1584366872000},"page":"00286-2019","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians"],"prefix":"10.1183","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-7233","authenticated-orcid":false,"given":"James A.","family":"Eaden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Skeoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Waterton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-3545","authenticated-orcid":false,"given":"Stephen M.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"2024101707473832000_6.1.00286-2019.1","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"2024101707473832000_6.1.00286-2019.2","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"2024101707473832000_6.1.00286-2019.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017"},{"key":"2024101707473832000_6.1.00286-2019.4","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101707473832000_6.1.00286-2019.5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1440-1843.2012.02187.x","article-title":"Drug-\/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis","volume":"17","author":"Amar","year":"2012","journal-title":"Respirology"},{"key":"2024101707473832000_6.1.00286-2019.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2018.PA2956"},{"key":"2024101707473832000_6.1.00286-2019.7","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-39"},{"key":"2024101707473832000_6.1.00286-2019.8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","article-title":"Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024101707473832000_6.1.00286-2019.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211779"},{"key":"2024101707473832000_6.1.00286-2019.10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12410-017-9415-3","article-title":"New imaging methods for detection of drug-induced cardiotoxicity in cancer patients","volume":"10","author":"Simoni","year":"2017","journal-title":"Curr Cardiovasc Imaging Rep"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00286-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:58Z","timestamp":1740373318000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00286-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,16]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1183\/23120541.00286-2019"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00286-2019","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}